Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBarr (A.G.) Regulatory News (BAG)

Share Price Information for Barr (A.G.) (BAG)

Share Price is delayed by 15 minutes
Get Live Data
618.00    5.00 (0.82%)
Bid:
617.00
Ask:
619.00
Spread: 2.00 (0.324%)
Market Cap: £685.83m
BAG Live PriceLast checked at - London Stock Exchange

Intraday Barr (A.G.) Share Chart

Trading Statement

30 Jul 2024 07:00

RNS Number : 2803Y
Barr(A.G.) PLC
30 July 2024
 

 IMMEDIATE RELEASE 30 July 2024

A.G. BARR p.l.c.

("A.G. BARR" or "the business")

 

Strong Revenue Growth And Margin Rebuild On Track

A.G. BARR p.l.c., the branded multi-beverage business with a portfolio of market-leading UK brands, today announces a trading update for the 26 weeks ended 27 July 2024.

Headlines

- A.G. BARR: H1 revenue growth of c.5% of which Soft Drinks growth was c.7%

- IRN-BRU: growth in volume and value supported by a highly successful Euros media campaign

- Rubicon: double digit growth with innovation, marketing investment and new distribution gains

- Boost: margin realignment and business integration on plan, production sourcing programme underway

Euan Sutherland, Chief Executive, commented:

"I am pleased to report overall H1 revenue growth of c.5% with Soft Drinks growth of c.7%, against strong prior year comparatives. The strategic margin rebuild programmes are on plan, guidance on revenue and margin remains unchanged, and we are on track to meet FY expectations*.

Our four power brands - IRN-BRU, Rubicon, Boost and FUNKIN - have clear paths to long term growth, supported by strong innovation programmes across all of our portfolio and opportunities to work even more closely to add value to our customers, in all channels.

We continue to invest in our supply chain which will deliver tangible benefits as we insource more of our volume, build capacity to support our growth plans, improve resilience and enhance our margins.

We have a clear and focussed UK based growth strategy with simple KPIs of Net Revenue, Operating Margin and ROCE."

Performance Highlights

Revenue for the first half of the financial year is expected to be c.£221m (2023/24 : £210.4m).

Soft Drinks

Strong Soft Drinks brand performance was led by Rubicon where successful marketing and further distribution gains drove double digit revenue growth. Revenue from IRN-BRU was up through a combination of volume and value growth and continued market share gains in England. As previously communicated, the focus for Boost this year is on margin build and insourcing of the operation and this continues on plan. 

Cocktail Solutions

The FUNKIN ready-to-drink (RTD) business has continued to grow at pace in our strategic growth channel of retail where it is the number 1 RTD cocktail brand. Strong off-trade growth was impacted by short term issues with third party can production and the ongoing challenges in the hospitality sector where late night venues remain particularly affected.

Other and Business Change Programme

MOMA maintained its growth in H1 with new distribution gains.

The Barr Direct route to market closed at the end of June with no impact to customer service. Symbol and Independent retailers are now fully serviced through the Wholesale Channel, supported by a larger Field Sales team.

The integration of Boost into Barr Soft Drinks is on track and will be completed in H2. Manufacturing synergies continue to be realised as production is insourced.

As previously stated, these two projects are expected to give rise to a one-off cost of c.£5m in the 2024/25 financial year, the majority of which will be incurred in H1. 

As previously communicated, Jonathan Kemp, Commercial Director, will retire later in the year and we are pleased to announce the appointment of Dino Labbate**. Dino joins in January, in a newly created, broader role of MD A.G. BARR, reporting to Euan Sutherland. Jonathan will not be replaced on the board and will remain with the business on a consultancy basis through to autumn 2025.

H2 Outlook

The half year trading performance is in line with our expectations. We remain committed to improving our profit margins which, combined with the forecast revenue growth, will lead to positive earnings momentum for H2 and beyond. The outlook for the full year remains unchanged and we are on track to meet FY expectations*.

For more information, please contact :

A.G. BARR Instinctif Partners

0330 390 3900 020 7457 2010/05

Euan Sutherland, Chief Executive Justine Warren

Stuart Lorimer, Finance Director Matthew Smallwood

 

 

* Analyst consensus : FY24 Net Revenue £421.2m, PBT £56.9m (FY23 PBT £50.5m)

** Dino Labbate is currently GB Commercial Director for Hospitality, Britvic PLC

 

Next update : Interim Results - 24 September 2024

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUKSNRSVUBUAR
Date   Source Headline
6th Jul 202112:11 pmRNSDirector/PDMR Shareholding
25th Jun 20217:00 amRNSDirectorate Changes
10th Jun 20219:01 amRNSHolding(s) in Company
8th Jun 20213:33 pmRNSDirector/PDMR Shareholding
28th May 202112:24 pmRNSResult of AGM
28th May 20217:00 amRNSAGM Statement
26th May 202111:01 amRNSDirectorship
11th May 202111:08 amRNSDirector/PDMR Shareholding
6th May 20218:13 amRNSHolding(s) in Company
27th Apr 20219:15 amRNSAnnual Report and Accounts / Notice of AGM
13th Apr 20218:18 amRNSDirector/PDMR Shareholding
12th Apr 202112:33 pmRNSDirector/PDMR Shareholding
1st Apr 20219:33 amRNSDirector/PDMR Shareholding
30th Mar 20217:00 amRNSFINAL RESULTS for the year ended 24 January 2021
8th Mar 202111:42 amRNSDirector/PDMR Shareholding
8th Feb 20211:00 pmRNSDirector/PDMR Shareholding
26th Jan 20217:00 amRNSTrading Update
21st Jan 202112:00 pmRNSNotice of Trading Update
11th Jan 202112:11 pmRNSDirector/PDMR Shareholding
8th Dec 202010:01 amRNSDirector/PDMR Shareholding
18th Nov 20202:00 pmRNSCompensation payment
9th Nov 202011:38 amRNSDirector/PDMR Shareholding
3rd Nov 20208:51 amRNSDirector/PDMR Shareholding
8th Oct 20202:02 pmRNSDirector/PDMR Shareholding
23rd Sep 20209:03 amRNSDirector/PDMR Shareholding
22nd Sep 20209:13 amRNSHolding(s) in Company
22nd Sep 20207:00 amRNSAG BARR p.l.c. Interim results
8th Sep 20201:46 pmRNSDirector/PDMR Shareholding
10th Aug 202010:35 amRNSDirector/PDMR Shareholding
28th Jul 20207:00 amRNSTrading Update
15th Jul 20207:00 amRNSHolding(s) in Company
8th Jul 20202:36 pmRNSDirector/PDMR Shareholding
25th Jun 20209:53 amRNSResult of AGM
23rd Jun 20205:06 pmRNSRockstar Contract Termination & COVID-19 Update
8th Jun 20203:16 pmRNSDirector/PDMR Shareholding
21st May 20209:13 amRNSNotice of Annual General Meeting
7th May 20204:48 pmRNSDirector/PDMR Shareholding
21st Apr 20209:27 amRNSAnnual Report nd Accounts
8th Apr 20203:30 pmRNSDirector/PDMR Shareholding
8th Apr 20207:00 amRNSFinal Results
6th Apr 20207:00 amRNSNotice of Revised Date of Final Results
30th Mar 20203:37 pmRNSHolding(s) in Company
23rd Mar 20207:16 amRNSFCA moratorium on publication of results
20th Mar 202010:10 amRNSHolding(s) in Company
11th Mar 20201:39 pmRNSResponse to PepsiCo To Acquire Rockstar
9th Mar 202011:54 amRNSDirector/PDMR Shareholding
10th Feb 20202:03 pmRNSDirector/PDMR Shareholding
28th Jan 20207:00 amRNSTrading Update
20th Jan 20207:00 amRNSTransaction in Own Shares
16th Jan 20201:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.